Annals of Nuclear Medicine

, Volume 34, Issue 1, pp 1–12 | Cite as

Nuclear oncology as seen by me in Japan: a historical review and future perspective

  • Yasuhito SasakiEmail author
Review Article


Since 1964 the author has seen and experienced the progress of nuclear medicine in Japan. The purpose of this review article is to trace the application of radiopharmaceuticals and instruments for the diagnosis of tumors and treatment of cancers in the past 55 years. The application of various radiopharmaceuticals for the detection of tumors and therapy of cancers are historically reviewed based on the author’s personal clinical experience and research work. Nuclear medicine has been advanced by coordinated developments of instruments and radiopharmaceuticals like two wheels of a vehicle. The journey of nuclear medicine in the past was not necessarily a smooth one having met with periodic difficulties that changed its direction. The ways by which nuclear oncology has progressed by having overcome episodic problems are described. Future perspectives focusing on the recent trend of theranostics are described with the emphasis on efforts being made by the leadership of JSNM to contribute to the progress of nuclear medicine worldwide. The author believes that the multi-and trans-disciplinary collaboration of related specialists as well as other concerned parties will be necessary for the further progress of nuclear oncology in the future.


Gastric cancer Bacterial overgrowth Carcinoembryonic antigen Glioblastoma Neuroendocrine tumors 



  1. 1.
    Nishiyama Y, Kinuya S, Kato T, et al. Nuclear medicine practices in Japan—a report of the eighth nationwide survey in 2017. Ann Nucl Med. 2019. Scholar
  2. 2.
    Ueda H, Sasaki Y, Moori M, Yamamoto M, Saito S, Unuma M, et al. A case report of liver cirrhosis due to Thorotorast and review of literatures. NAIKA. 1966;17:960–8 (in Japanese).PubMedGoogle Scholar
  3. 3.
    Osada T, Inoue T, Tanaka K, Maeda S, Ohara H, Sasaki Y, et al. A case of primary aldosteronism. J St. Marianna Univ. 1976;4:133–8 (in Japanese).Google Scholar
  4. 4.
    Kado B, Nakajima T, Sakura M, Sasaki Y, Nagai T. Clinical evaluation of bone scan using Tc-99m methylene diphosphonate. Kaku Igaku (Jpn J Nucl Med). 1979;16:95–103 (in Japanese).Google Scholar
  5. 5.
    Ueda H, Sasaki Y, Iio M, Kaihara S, Machida K, Iwao I, et al. Catheter semiconductor radiation detector for continuous measurement of cardiac output. J Nucl Med. 1969;10:713–21.PubMedGoogle Scholar
  6. 6.
    Sasaki Y, Wagner HN Jr, Iio M, Murao S, Takayanagi S, Kobayashi T. Catheter semiconductor detector and its application to clinical and experimental medicine. In: Hoffer BH, Beck RN, Gottschalk A, editors. Semiconductor detectors in the future of nuclear medicine. New York: The Society of Nuclear Medicine Inc; 1971. p. 144–56.Google Scholar
  7. 7.
    Takayanagi S, Kobayashi T, Sugita T, Iio M, Sasaki Y. Developmet of various catheter semiconductor radiation detectors and their application to clinical medicine. IEEE Trans Nucl Sci. 1972;NS19:226–36.CrossRefGoogle Scholar
  8. 8.
    Sasaki Y, Iio M, Kameda H, Ueda H, Aoyagi T, Christopher N, et al. Measurements of 14C-lactose absorption in the diagnosis of lactase deficiency. J Lab Clin Med. 1970;10:824–35.Google Scholar
  9. 9.
    Sherr HP, Sasaki Y, Newman A, Banwell JG, Wagner HN Jr, Hendrix TR. Detection of bacterial deconjugation of bile salts by a convenient breath-analysis technic. N Engl J Med. 1971;285:655–61.CrossRefGoogle Scholar
  10. 10.
    Sasaki Y. Carbon-14 and carbon-13 breath tests. In: Wagner Jr HN, Szabo Z, Buchanan JW, editors. Principle of nuclear medicine. Philadelphia: Sounders; 1995.Google Scholar
  11. 11.
    Tsujino D, Sasaki Y, Chida R, Kusakari K, Okabe K, Ogata M, et al. Basic studies and clinical applications of a radioimmunoassay kit for carcinoembryonic antigen. Kaku Igaku (Jpn J Nucle Med). 1976;13:533–41 (in Japanese).Google Scholar
  12. 12.
    Tsujino D, Sasaki Y, Chida R, Someya K, Kusakari K, Okabe K, et al. Clinical significance of CEA measurements. J St Marianna Univ. 1978;6:263–75 (in Japanese).Google Scholar
  13. 13.
    Takahashi T, Tsujino D, Kato Y, Wada Y, Someya K, Itagaki K, et al. Clinical evaluation of radioimmunoscintigraphy using a I-131 anti CEA and CA19-1 monoclonal antibodies cocktail (IMACIS-1). Jpn J Cancer Clin. 1989;35:828–33.Google Scholar
  14. 14.
    Sasaki Y, Inoue T, Oriuchi N, Mitsuhashi N, Nagai T, Igarashi H, et al. Clinical evaluation of immunoscintigraphy with 131I anti-CEA and 131I anti-CA19-9 monoclonal antibody cocktail (IMACIS-1)—report of the phase II study. Kaku Igaku (Jpn J Nucl Med). 1990;27:349–62.Google Scholar
  15. 15.
    Sasaki Y, Yamamoto M, Hoshi K, Kashiwada K, Someya K, Sugiyama C, et al. Myocardial scan using 201TlCl. Kaku Igaku (Jpn J Nucl Med). 1978;15:577–85 (in Japanese).Google Scholar
  16. 16.
    Nakajima T, Kado B, Sakura M, Tabei T, Sasaki Y, Nagai T. Clinical evaluation of tumor scintigraphy with 201Tl-chloride. Radioisotopes. 1978;27:477–80 (in Japanese).CrossRefGoogle Scholar
  17. 17.
    Oriuchi N, Tamura M, Shibazaki T, Inoue T, Watanabe N, Tateno M, et al. Evaluation of 201Tl SPECT in patients with glioma: a comparative study with historical diagnosis, clinical feature and proliferative activity. Kaku Igaku (Jpn J Nucl Med). 1991;28:1263–71 (in Japanes).Google Scholar
  18. 18.
    Tsushima Y, Higuchi T, Sudo T, Nagai T, Ishihara T, Shibasaki T, et al. The origin of PET/CT—the world’s first parallel type PET/CT installed by Hitachi at Gunma University. Medix. 2017;64:8–13 (in Japanese).Google Scholar
  19. 19.
    Beyer T, Townsend DW, Czernin J, Freudenberg LS. The future of hybrid imaging—part 2: PET/CT. Insights Imaging. 2011;2:225–34.CrossRefGoogle Scholar
  20. 20.
    Takano S, Kobayashi N, Kaneta T, Hata M, Ichikawa Y, Inoue T. Theranostics of neuroendocrine tumors—present states and future prospects of peptide radionuclide therapy. Nucl Med Clin. 2018;51:38–42 (in Japanese).Google Scholar
  21. 21.
    Kuwabara Y, Koizumi K, Ushiyama Y, Kinuya S, Takeoka H, Takeda T, et al. Nuclear medicine practice in Japan: a report of the sixth nationwide survey in 2007. Ann Nucl Med. 2009;23:209–15.CrossRefGoogle Scholar
  22. 22.
    Wagner HN. A personal history of nuclear medicine. London: Springer; 2006. p. 69.Google Scholar
  23. 23.
    ICRP Publication 128. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44(2S):7–321.Google Scholar
  24. 24.
    Kinuya S. Activities for the development of targeted radionuclide therapy in Japan. Nucl Med Mol Imaging. 2019;53:35–7.CrossRefGoogle Scholar
  25. 25.
    Nakamoto Y, Ishimori T, Sano K, Shimizu Y, Togashi K. Clinical feasibility of early scanning after administration of 68Ga-DOTATOC. Ann Nucl Med. 2019;33:55–60.CrossRefGoogle Scholar
  26. 26.
    Joraku A, Hatano K, Kawai K, et al. Phase I/IIa PET imaging study with 89-zirconium labeled anti-PSMA minibody for urological malignancies. Ann Nucl Med. 2019;33:119–27.CrossRefGoogle Scholar
  27. 27.
    Ishizaki A, Mishiro K, Shiba K, et al. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives. Ann Nucl Med. 2019;33:244–51.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Research Center for Radiation OncologyShonan Kamakura General Hospital Affiliated Clinical Research CenterKamakuraJapan

Personalised recommendations